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University of Medical Sciences, Kashan, Iran
ABSTRACT
Objective: This research was conducted to assess the effects of coenzyme Q10 (CoQ10) intake on gene
expression related to insulin, lipid and inflammation in subjects with polycystic ovary syndrome (PCOS).
Methods: This randomized double-blind, placebo-controlled trial was conducted on 40 subjects diagnosed
with PCOS. Subjects were randomly allocated into two groups to intake either 100mg CoQ10 (n¼ 20) or
placebo (n¼ 20) per day for 12weeks. Gene expression related to insulin, lipid and inflammation were
quantified in blood samples of PCOS women with RT-PCR method.
Results: Results of RT-PCR shown that compared with the placebo, CoQ10 intake downregulated gene
expression of oxidized low-density lipoprotein receptor 1 (LDLR) (p< 0.001) and upregulated gene expres-
sion of peroxisome proliferator-activated receptor gamma (PPAR-c) (p¼ 0.01) in peripheral blood mono-
nuclear cells of subjects with PCOS. In addition, compared to the placebo group, CoQ10 supplementation
downregulated gene expression of interleukin-1 (IL-1) (p¼ 0.03), interleukin-8 (IL-8) (p¼ 0.001) and tumor
necrosis factor alpha (TNF-a) (p< 0.001) in peripheral blood mononuclear cells of subjects with PCOS.
Conclusions: Overall, CoQ10 intake for 12weeks in PCOS women significantly improved gene expression
of LDLR, PPAR-c, IL-1, IL-8 and TNF-a.
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Introduction
Polycystic ovary syndrome (PCOS) is a prevalent heterogeneous
complication related to disorders of reproductive, metabolic and
endocrine function [1]. The prevalence of PCOS among repro-
ductive-aged women was reported 6–25%, depending on defined
criteria [2]. Previous evidences show that PCOS is associated
with hyperandrogenism and metabolic variations including insu-
lin resistance and lipid disorders [3]. In addition, a relation has
been observed between pro-inflammatory genotypes and PCOS,
linked to polymorphism of genes coding for tumor necrosis fac-
tor alpha (TNF- a) and interleukin 6 (IL-6) [4].
Coenzyme Q10 (CoQ10) is a nutrient that plays an important
function in the production of cellular energy as well as acts in
scavenging free radicals and inhibiting lipid and protein oxida-
tion as an antioxidant [5]. Previously, beneficial effects of CoQ10
on gene expression related to insulin, lipid and inflammation
among subjects without PCOS have evaluated. Tarry-Adkins
et al. [6] found that postweaning dietary intake of recuperated
animals with CoQ10 prevented the programed reduction in insu-
lin receptorsubstrate-1 and p110-b and the programed increased
in IL-6. In addition, in another study was seen that CoQ10
administration at a dosage of 20mg/kg increased insulin sensitiv-
ity and had antidiabetic properties via increasing activity of phos-
phatidylinositol kinase (PI3K) in rats fed a high-fat, high-fructose
diet [7]. Mediterranean diet with CoQ10 also modified gene
expression of pro-inflammatory markers among elderly men and
women for four weeks [8].
This evidence might support the importance of CoQ10
administration in women with PCOS. According to the best of
our knowledge, data on the effects of CoQ10 intake on gene
expression related to insulin, lipid and inflammation in subjects
with PCOS are limited. The objective of our study was to deter-
mine the effects of CoQ10 on gene expression related to insulin,
lipid and inflammation in subjects with PCOS.
Subjects and methods
Trial design and participants
This randomized double-blind placebo-controlled clinical trial,
registered in the Iranian website for registration of clinical trials
(http://www.irct.ir: IRCT201605225623N80), was done among 40
subjects with PCOS diagnosed according to the Rotterdam crite-
ria [9] aged 18–40 years old who referred to the Kosar Clinic in
Arak and the Persian Gulf Martyrs Hospital in Bushehr, Iran,
between May 2016 and September 2016. We excluded pregnant,
elevated levels of prolactin, endocrine diseases and no hormonal
treatments in the previous 6months in the study. This research
was approved by the ethics committee of Arak University of
Medical Sciences (AUMS) and informed consent form was taken
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from all subjects. All subjects were matched according to age,
phenotypes of PCOS and BMI at the study baseline. Subjects
were then randomly divided into two groups to receive either
CoQ10 (n¼ 20) or placebo (n¼ 20) for 12weeks. CoQ10 and its
placebos (cellulose) were provided by Nature Made
Pharmaceutical Company (New York, NY, USA) and Barij
Essence Pharmaceutical Company (Kashan, Iran), respectively.
Treatment adherence
To evaluate the compliance, we counted the remaining supple-
ments. To increase compliance, all women received short mes-
sages every day to remind them about taking the capsules.
Assessment of anthropometric measures
Weight and height of participants were determined in an over-
night fasting status using a standard scale (Seca, Hamburg,
Germany) at the beginning of the study and after 12-weeks’
intervention. BMI was calculated as weight in kg divided by
height in meters squared.
Assessment of outcomes
In our study, gene expression of peroxisome proliferator-acti-
vated receptor gamma (PPAR-c) and glucose transporter 1
(GLUT-1) were considered as the primary outcome and gene
expression of lipoprotein(a) [Lp(a)], oxidized low-density lipo-
protein receptor 1 (LDLR), interleukin-1 (IL-1), interleukin-8
(IL-8), tumor necrosis factor alpha (TNF-a) and transforming
growth factor beta (TGF-b) were considered as the secondary
outcomes.
Isolation of lymphocyte cells
At baseline and endpoint of the intervention, 10ml samples of
venous blood were taken after overnight fasting at Arak reference
laboratory. Then, lymphocyte cells were extracted from blood
samples of subjects with PCOS by the use of a 50% percoll
(Sigma-Aldrich, Dorset, UK). Samples were taken for cell
count and viability testing by trypan blue, RNA and DNA extrac-
tion [10].
RNA extraction and real-time PCR
To RNA extraction, we used the RNX-plus kit (Cinnacolon,
Tehran, Iran). RNA suspension was frozen in 20 C until
cDNA making. Following extraction of the total RNAs from each
sample, RNA quantification were performed by UV spectropho-
tometer. Each samples OD 260/280 ratio between 1.7 and 2.1
was intended that shows no contamination with both protein
and DNA [10]. The isolated RNA was reverse transcribed to
cDNA library using moloney murine leukemia virus (MMLV)
reverse transcriptase (RT). Gene expression of PPAR-c, GLUT-1,
Lp(a) and LDLR were evaluated by quantitative RT-PCR, using
the LightCycler technology (Roche Diagnostics, Rotkreuz,
Switzerland) with SYBR green detection and Amplicon Kit
(Table 1). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
primers were used as housekeeping gene. To design primers,
Primer Express Software (Applied Biosystems, Foster City, CA,
USA) and Beacon designer software (Takaposizt, Tehran, Iran)
were used. Relative transcription levels were calculated by the
method of Pffafi or 2DDCT.
Randomization
Randomization assignment was done using computer-generated
random numbers as blindness by a trained staff at the gyne-
cology clinic.
Statistical methods
To establish normal data distribution, we used the
Kolmogrov–Smirnov test. To establish differences in anthropo-
metric measures as well as in macro- and micro-nutrient dietary
intakes between the two groups, we applied independent samples
t-test. To determine the effects of CoQ10 supplementation on
gene expression involved in lipid, insulin and inflammation sig-
naling pathway, we used independent samples t-test. The p<0.05
were considered statistically significant. All data entry and
Table 1. Specific primers used for real-time quantitative PCR.
Gene Primer Product size (bp) Annealing temperature (C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
PPAR-c F: ATGACAGACCTCAGACAGATTG 210 54
R: AATGTTGGCAGTGGCTCAG
GLUT-1 F: TATCTGAGCATCGTGGCCAT 238 62.1
R: AAGACGTAGGGACCACACAG
Lp(a) F: GACACAGCACGTTCATTCCA 200 55
R: ACACCCCCCTACAATGCTTC
LDLR F: ACTTACGGACAGACAGACAG 223 57
R: GGCCACACATCCCATGATTC
IL-1 F: GCTTCTCTCTGGTCCTTGG 174 56
R: AGGGCAGGGTAGAGAAGAG
IL-8 F: GCAGAGGGTTGTGGAGAAGT 150 56
R: ACCCTACAACAGACCCACAC
TNF-a F: GTCAACCTCCTCTCTGCCAT 188 52
R: CCAAAGTAGACCTGCCCAGA
TGF-b F: TTGAGACTTTTCCGTTGCCG 227 56
R: CGAGGTCTGGGGAAAAGTCT
GAPDH: glyceraldehyde-3-Phosphate dehydrogenase; GLUT-1: glucose transporter 1; IL-1: interleukin-1; IL-8: interleukin-
8; Lp(a): lipoprotein(a); LDLR1: oxidized low-density lipoprotein receptor 1; PPAR-c: peroxisome proliferator-activated
receptor gamma; TNF-a: tumor necrosis factor alpha; TGF-b: transforming growth factor beta.
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statistical analyzes were conducted using the Statistical Package
for Social Science version 18 (SPSS Inc., Chicago, IL, USA).
Results
At baseline, we were invited 55 women; however, 15 women
were excluded from the study because of not meeting inclusion
criteria. In the current study, 40 women [placebo (n¼ 20) and
CoQ10 (n¼ 20)] completed the trial (Figure 1).
Mean age, height, and weight and BMI at baseline and end-
of-trial were not statistically different between the two groups
(Table 2).
Results of RT-PCR indicated that compared with the placebo,
CoQ10 intake downregulated gene expression of LDLR
(p< 0.001), but did not affect gene expression of LP(a) in periph-
eral blood mononuclear cells of subjects with PCOS (Figure 2).
We found that CoQ10 intake, compared with the placebo,
upregulated gene expression of PPAR-c (p¼ 0.01), but
unchanged gene expression of GLUT-1 in peripheral blood
mononuclear cells of subjects with PCOS (Figure 3).
Compared with the placebo, CoQ10 intake downregulated
gene expression of IL-1 (p¼ 0.03), IL-8 (p¼ 0.001) and TNF-a
(p< 0.001), but did not influence gene expression of TGF-b in
peripheral blood mononuclear cells of subjects with PCOS
(Figure 4).
Discussion
However, in another study, we have previously shown beneficial
effects of CoQ10 on insulin metabolism and some lipid profiles
in patients with PCOS [11], to our knowledge, this trial is the
first evaluating effects of CoQ10 on gene expression related to
insulin, lipid and inflammation among women with PCOS. We
demonstrated that CoQ10 intake for 12weeks among subjects
with PCOS had beneficial effects on few gene expression related
to insulin, lipid and inflammation.
Subjects with PCOS are susceptible to some metabolic disor-
ders and inflammation [12,13]. We found that taking CoQ10 for
12weeks in subjects with PCOS downregulated LDLR expression,
but did not affect Lp(a) expression. Tsai et al. [14] seen that
CoQ10 rescued dephosphorylation of AMP-activated protein kin-
ase (AMPK) caused by Ox-LDL. In addition, CoQ10 attenuated
the Ox-LDL-induced generation of reactive oxygen species (ROS)
[15]. Prior genetic and epidemiologic studies have shown that
Ox-LDL and Lp(a) are risk factors of atherosclerotic diseases
such as CHD [16–18]. CoQ10 intake mat decrease Ox-LDL-
induced endothelial oxidative injuries by the modulation of
LOX-1-mediated ROS generation via the AMPK/PKC/NADPH
oxidase signaling pathway [14].
This research demonstrated that CoQ10 supplementation for
12weeks in subjects with PCOS upregulated PPAR-c expression,
but unchanged GLUT-1 expression. However, data on the effects
of CoQ10 intake on gene expression of PPAR-c and GLUT-1 are
scarce; few studies have evaluated the effects of CoQ10 on gene
expression related to insulin. Lee et al. [19] found that CoQ10
increased gene expression of PPAR-a at both the mRNA and
protein levels in 3T3-L1preadipocytes. In addition, supplementa-
tion with CoQ10 induced gene expression of PPAR-a in SAMP1
mice [20]. In another study, CoQ10 supplementation increased
p110b protein expression both liver and skeletal muscle [6]. This
is consistent with prior studies indicating that administration of
a much higher dose of CoQ10 (20mg/kg) affects insulin sensitiv-
ity and had antidiabetic properties via increasing the activity of
phosphatidylinositol kinase (PI-3Ks) in rats fed with a high-fat,
high-fructose diet [7]. PPAR-c is primarily present in adipocytes,
which plays an important function in glucose and insulin metab-
olism [21]. CoQ10 intake may induce PPAR-c expression thor-
ough the calcium-mediated AMPK signal pathway and
suppressing differentiation-induced adipogenesis [19].
Randomized (n=40) 
Allocated to placebo (n=20) 
Lost to follow-up (n=0) 
Analyzed (n=20) 
Allocated to intervention (n=20) 
Lost to follow-up (n=0) 
Analyzed (n=20) 
Assessed for eligibility (n=55) 
Excluded (n=15)  
- Not meeting inclusion criteria (n=10)  
- Not living in Arak (n=5)  
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Figure 1. Summary of patient flow diagram.
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Figure 2. Effect of 12-week supplementation with CoQ10 or placebo on expression ratio of Ox-LDL and Lp(a) gene in blood mononuclear cells of PCOS women.
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Figure 3. Effect of 12-week supplementation with CoQ10 or placebo on expression ratio of PPAR-c and GLUT-1 gene in blood mononuclear cells of PCOS women.
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Figure 4. Effect of 12-week supplementation with CoQ10 or placebo on expression ratio of IL-1, IL-8, TNF-a and TGF-b gene in blood mononuclear cells of PCOS
women.
Table 2. General characteristics of study participants.
Placebo group (n¼ 20) CoQ10 group (n¼ 20) pa
Age (y) 24.7 ± 5.3 24.9 ± 3.7 0.91
Height (cm) 162.5 ± 6.6 160.8 ± 7.8 0.47
Weight at study baseline (kg) 76.5 ± 17.1 71.6 ± 11.1 0.29
Weight at end-of-trial (kg) 76.1 ± 17.7 71.9 ± 10.8 0.36
Weight change (kg) 0.4 ± 1.0 0.3 ± 5.7 0.63
BMI at study baseline (kg/m2) 28.9 ± 6.6 27.7 ± 3.6 0.44
BMI at end-of-trial (kg/m2) 28.8 ± 6.7 27.8 ± 3.6 0.54
BMI change (kg/m2) 0.1 ± 0.3 0.1 ± 2.1 0.61
Data are means ± SDs.
aObtained from independent t-test.
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We found that taking CoQ10 for 12weeks in subjects with
PCOS downregulated gene expression of IL-1, IL-8 and TNF-a
compared with the placebo, but did not affect gene expression
of TGF-b. Yoneda et al. [22] demonstrated that CoQ10
reduced gene expression of interleukin-1b, TNF-a and nuclear
factor-jB (NF-KB) in rats after 8 days. In another study,
CoQ10 supplementation significantly reduced the IL-6 protein
and TGF-b1 and Lep mRNA levels [6]. In addition, our study
was in agreement with findings in cardiac tissue [23], and
CoQ10 is known to have anti-inflammatory properties in
mouse liver [24] and human plasma [25]. Also, gene expres-
sion of TNF-a were significantly decreased following CoQ10
intake in an experimental model of multiple sclerosis for three
weeks [26]. Increased inflammatory cytokines would result in
the development of insulin resistance via the inhibition of
insulin signaling through activation of the inhibitory-jB kin-
ase-b and c-Jun N-terminal kinase pathways [27]. Moreover,
inflammation in subjects with PCOS render them at an
increased risk for the development of atherosclerosis and infer-
tility [28]. Due to its antioxidant and radical scavenging activ-
ity, CoQ10 can reduce ROS production and free radicals,
which in turn could affect gene expression of TNF-a via the
NF-jB pathway [29].
The current study had few limitations. We did not evaluate
CoQ10 levels at baseline and at the end-of-trial. Furthermore,
in the current study, we considered PPAR-c and GLUT-1 as
gene expressions involved in the insulin signaling pathway.
However, GLUT-1 is not directly influenced by insulin, it is
not surprising whether we did not observe any variation of
GLUT-1 gene expression following the supplementation of
CoQ10. We agree that other insulin-dependent transporters
such as GLUT-4 or other post-receptor steps including insulin
receptor substrate 1 or-2 and PKB are more important than
GLUT-1. Unfortunately, we did not assess gene expression of
these pathways. Therefore, measurement of these pathways is
suggested in future studies.
Overall, CoQ10 supplementation for 12weeks in PCOS
women significantly improved gene expression of LDLR,
PPAR-c, IL-1, IL-8 and TNF-a, but did not affect gene expres-
sion of Lp(a), GLUT-1 and TGF-b.
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